Pharmaceutical

Ascidian launches first-ever clinical study of RNA exon editor for vision loss

An eye-catching milestone in hand, Ascidian will begin the Phase I/II STELLAR study of ACDN-01 for Stargardt disease in H1 2024.

Jan 29, 2024 - 18:00
Ascidian launches first-ever clinical study of RNA exon editor for vision loss
An eye-catching milestone in hand, Ascidian will begin the Phase I/II STELLAR study of ACDN-01 for Stargardt disease in H1 2024.
Read the original article

Tags:

Previous Article

King Charles’ diagnosis raises awareness on prostate condition 

Next Article

Moderna leads the development of mRNA vaccines in infectious diseases

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Medicare advisers endorse reforms to lower drug spending

STAT+: Medicare advisers endorse reforms to lower drug ...

Apr 13, 2023

Is the flu shot market a slam dunk for mRNA vaccines? Experts aren’t so sure

Is the flu shot market a slam dunk for mRNA vaccines? E...

Dec 5, 2023

Amicus gears up to launch Pompe disease combination therapy in the UK

Amicus gears up to launch Pompe disease combination the...

Aug 16, 2023